How Did JP Morgan Really Do?

JP Morgan (JPM) was the first of the major banks to report second quarter earnings and the headline figures were quite positive. Quarterly profits rose 76% to $4.8 billion or $1.09 per share, and analysts’ expected the company to report just 70 cents per share. The better performance was thanks in large part to slimmer loan losses and lower credit costs. Furthermore, credit cards and retail banking both had long been a drag on JP Morgan’s performance actually both swung to a profit in the second quarter. However, somewhat troubling was the fact that revenues actually dropped nearly 8 percent to $25.6 billion, as investment banking and trading revenue both sagged. This drop in revenues was expected as the results were in-line with consensus analysts’ estimates.
So, JP Morgan, the nation’s second largest bank by assets, saw earnings soar while revenue declined sharply. Sure, we know that credit conditions have improved, but even CEO Jamie Dimon said that delinquencies and charge-offs remained unacceptably high. The factor that is going somewhat unnoticed is the fact that the company lowered their loan-loss reserves by $1.5 billion, which padded this quarter’s profits. JP Morgan’s management team has been upfront about the reduction to reserves and warned that these results do not represent “normal ongoing earnings”. However, the 23% reduction in reserves is a sign of confidence that current improving trends in credit will continue in the coming months.
At Ockham, our view of the quarter is mixed as trading revenues and fees from investment banking were rather anemic, yet credit concerns are easing to the point that they can take funds out of their reserves. We recently upgraded JPM to Undervalued and we think the stock could easily increase by 20% based on current fundamentals. For example, over the last ten years JPM has normally traded between 16.5x to 33.8x times cash earnings per share, but that is down to only about 12x at the current price. Furthermore, the company trades at only 1.39x revenue per share, which compares favorably to the historically normal valuation of 1.49x to 2.50x.
JP Morgan has strengthened its balance sheet considerably and now has tier one capital of 12.1%, up from 9.7% at this time a year ago. We would like to see management begin to ratchet up that dividend but at this point Mr. Dimon believes there are better uses of capital. For example, the company bought back $500 million in stock and plans to continue to do that “opportunistically”.
Overall, we think this quarterly report was not a home-run, but JPM also did not strike out. It was a solid base hit for the only major US bank that managed to not turn in a quarterly loss during the depths of the recession. For value-oriented investors, we think that JP Morgan is among the most attractive stocks in the financial sector. It is well run and we are finally starting to see better trends in consumer credit. Furthermore, we expect that JPM will begin to increase the dividend back to more historically normal levels in the coming quarters.
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.

